U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916546) titled 'SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC' on March 31.
Brief Summary: This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitors (TACE-L-P) in patients with HCC beyond up-to-seven criteria or with portal vein tumor thrombus (PVTT). Tumor response, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between the two groups.
Study Start Date: June 01, 2022...